What is EdiGene?
Headquartered in Beijing, EdiGene operates at the intersection of advanced molecular biology and clinical medicine. The company specializes in leveraging cutting-edge genome editing technologies to address unmet medical needs. By focusing on the development of novel therapeutics, EdiGene aims to redefine the standard of care for patients suffering from a broad spectrum of genetic diseases and cancer. Its market position is characterized by a research-intensive approach, supported by a sophisticated intellectual property portfolio and a commitment to high-impact scientific innovation.
How much funding has EdiGene raised?
EdiGene has raised a total of $154.5M across 3 funding rounds:
Series A
$14.5M
Other Financing Round
$11M
Series B
$129M
Series A (2018): $14.5M with participation from WI Harper Group, IDG, Lilly Asia Ventures, and Huagai Capital
Other Financing Round (2019): $11M led by IDG Capital Partners and Lilly Asia Ventures
Series B (2021): $129M supported by Lilly Asia Ventures, Kunlun Capital, 3H Health Investment, IDG Capital Partners, Loyal Valley Capital, Huagai Capital, Alwin Capital, Sherpa Healthcare Partners, BioTrack Capital, and Sequoia Capital
Key Investors in EdiGene
Lilly Asia Ventures
A leading biomedical venture capital firm with a global footprint, dedicated to partnering with exceptional entrepreneurs to develop breakthrough products that improve human health.
IDG Capital Partners
A premier investment firm with a long history of fostering growth in the technology and healthcare sectors through private equity and venture capital initiatives.
Sequoia Capital
A globally recognized venture capital firm known for its unparalleled track record in partnering with entrepreneurs to build market-leading companies across various industries.
What's next for EdiGene?
Looking ahead, EdiGene is poised to leverage its recent capital influx to transition its lead candidates through critical clinical trial phases. The strategic focus will likely remain on scaling its R&D infrastructure and strengthening its pipeline of gene-based therapies. As the company matures, the emphasis will shift toward regulatory milestones and potential commercialization pathways, ensuring that its genome editing innovations reach the patients who need them most. The continued support from top-tier venture capital firms suggests a long-term commitment to establishing EdiGene as a leader in the next generation of precision medicine.
See full EdiGene company page
